← Back to Clinical Trials
Recruiting NCT06722066

NCT06722066 Impact of Aortic Annulus Calcification on Long-Term Outcomes Following Transcatheter Aortic Valve Replacement: SAINT-TAVR Calcium Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06722066
Status Recruiting
Phase
Sponsor Eunpyeong St. Mary's Hospital
Condition Aortic Stenosis
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2024-10-02
Primary Completion 2031-12-02

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2024-10-02 with a primary completion date of 2031-12-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the long-term effects of aortic valve annular calcification in patients undergoing transcatheter aortic valve replacement (TAVR). The main question it aims to answer is: Does the degree of aortic valve annular calcification prior to TAVR influence long-term clinical outcomes, including major adverse cardiovascular events including all-cause mortality, over a 3-year period? Participants who have undergone TAVR as part of their regular medical care for severe aortic stenosis will have their pre-procedural imaging and clinical outcomes evaluated for a 3-year follow-up period.

Eligibility Criteria

Inclusion Criteria: 1. Adults aged 19 years or older. 2. Patients who have undergone transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. 3. Individuals who have voluntarily provided written informed consent to participate. Exclusion Criteria: 1\. Individuals who have not provided written informed consent for this study.

Contact & Investigator

Central Contact

Osung Kwon, MD. PhD

✉ oscaesar@gmail.com

📞 +82-10-3708-5673

Frequently Asked Questions

Who can join the NCT06722066 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Aortic Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06722066 currently recruiting?

Yes, NCT06722066 is actively recruiting participants. Contact the research team at oscaesar@gmail.com for enrollment information.

Where is the NCT06722066 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT06722066 clinical trial?

NCT06722066 is sponsored by Eunpyeong St. Mary's Hospital. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology